Abstract: Galectin-1 polypeptide variants that include a mutation of the histidine residue corresponding to position 52 of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the mutation being a substitution of the histidine to tyrosine or asparagine, providing resistance to acidosis otherwise resulting in deactivation of the native human Gal-1. The Galectin-1 polypeptide variants may include one or more additional mutation(s) of the cysteine residue corresponding to a position selected from 2, 16, 88, or combinations thereof of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the additional mutation being a substitution of the cysteine to serine, and providing resistance to oxidation.

Abstract: Bi-structured matrix for purification and handling of solid reagents, which comprises at least a polymer solid carrier coated with at least one hydrosoluble polymer, and manufacturing processes. The solid carrier may be, among others, cross-linked polyurethane foam or a micropipette tip. The hydrosoluble polymer may be, among others, polyvinylalcohol, agarose, hydroxyethylcellulose or combinations thereof. The matrix may further comprise a polymer produced from monomers of glycidyl metacrylate (GMA), dimethyl acrylamide (DMAAm), 2-hydroxyethyl metacrylate, metacrylic acid, or combinations thereof.

Abstract: The present invention provides isolated HaHB11 polypeptides and nucleic acids encoding the same. Also provided are methods of introducing a nucleic acid encoding HaHB11 polypeptides into a plant cell, plant part or plant, e.g., to increase tolerance to abiotic stress, to delay development and/or prolong the life span of a plant, and/or to increase yield from the plant. The invention also provides nucleic acids comprising HaHB11 promoter sequences and methods for expressing a nucleotide sequence of interest operably associated with the HaHB11 promoters of the invention in a plant cell, plant part, or plant. Also provided are transformed plants, plant tissues, plant cells and plant seed comprising the nucleic acids, expression cassettes and vectors of the invention.

Abstract: The present disclosure provides a novel modified gene, rGRF3, or an ortholog thereof, which is shown to be decoupled from control by miR396, particularly in the presence of over-expression of at least one GIF gene, such as GIF1, AtGIF 2, AtGIF 3, Os11g40100, Os12g31350, Os03g52320 or combinations thereof. When present in a plant, the rGRF3 results in a phenotype of increased productivity (e.g. increased yield, increased biomass, increased stress resistance, increased seed production, increased seed yield, increased root growth, increased root elongation speed, delayed leaf senescence or increased drought tolerance and combinations thereof).

Abstract: The present invention relates to a method of enhancing the activity of a transcription factor in a plant comprising expressing in said plant a chimeric protein comprising a GIF moiety comprising a GIF domain or fragment thereof, and a DNA binding domain (DBD) moiety. The chimeric proteins comprise a GIF moiety comprising a GIF domain or fragment thereof, or a polypeptide with an amino acid sequence having at least 85%, preferably at least 90%, even more preferably at least 95% sequence identity to the amino acid sequence of a GIF domain or fragment thereof; and a DBD moiety comprising the DBD or plant transcription factor whose activity enhancement is intended, or a binding protein which is capable of forming a tertiary complex with the DBD or transcription factor whose activity modification and/or enhancement is intended. The invention also relates to polynucleotides and polypeptides useful in the method of the invention.

Abstract: A process for producing propylene glycol from glycerol including a catalyst of Cu and Ce at concentrations of up to 15% of each metal. In addition, it is described a catalyst of Cu and Ce to perform the selective reduction of glycerol and the process of production of such catalyst.

Abstract: The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.

Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.

Abstract: The present invention relates to compositions and methods for preventing and treating cell proliferation in cancer. More specifically, the present invention relates to compositions and methods for inhibiting tumor growth, and for treating proliferative diseases, particularly colon and breast cancer, with a combined pharmacological approach. Yet more specifically, the compositions for inhibiting tumor growth comprise a combination of: i) a first component which is an ACSL4 inhibitor; and ii) a second component selected from the group consisting of mTOR inhibitor and ER inhibitor.

Abstract: Low-cost and easily-operated microviscometer suitable for medical diagnosis clinical studies and other fluid tests. The equipment consists of a microchannel (2) formed by concatenated microchannels made by micro-manufacturing techniques, and a fluid column position detector inside the microchannel. The microchannels are open at one end and closed at the other end and are made of a single biocompatible material. When a liquid drop is put into the inlet of the microchannel (2), the fluid enters by capillary until the compressed air pressure equals the capillary pressure plus atmospheric pressure. The fluid transient movement from entering the channel until stopping at its balance position is analyzed thus obtaining as a result the viscosity and the capillary pressure of the liquid tested.

Abstract: Recombinant bacterial strains comprising heterologous nif genes in its genome, and capable of fixing nitrogen. The strain may be, for example, a recombinant Pseudomonas fluorescens strain comprising heterologous nif genes in its genome. An inoculum and a method for increasing plant productivity are further described.

Abstract: Polypeptide having activity inducing pathogen plant defence, nucleotide sequence encodes it, microorganism, compositions and methods. The polypeptide is a subtilisin derived from a strain of Acremonium strictum. The polypeptide is encoded by the nucleotide sequence SEQ ID NO: 1 or sequences at least 90% homologous to the same and has the amino acid sequence SEQ ID NO: 2 or sequences at least 90% homologous to the same.

Abstract: Adjuvant for vaccines that comprises a non-lipidated bacterial outer-membrane polypeptide (Omp), in which the bacteria may be of those of Brucella genus. The adjuvant may be a modified polypeptide or may be, for example, the Omp19S polypeptide or the Omp16S polypeptide, parts or mixtures of the two. In a preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 1, or parts thereof. In a further preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 2 or parts thereof.

Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGF?-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.

Abstract: The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

Abstract: The present invention concerns methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer, wherein the methods comprise delivering a dominant-negative inhibitor of endogenous ErbB-2.

Abstract: Antimicrobial peptides set forth in SEQ ID Nos: 1-5 are described. The peptides have activity against Gram positive bacteria and against Gram negative bacteria. A bactericidal composition is also provided, which may comprise an amount between 0.5 ?g/mL and 1024 ?g/mL of the peptides and excipients.

Abstract: Polypeptide having activity inducing pathogen plant defense, nucleotide sequence encodes it, microorganism, compositions and methods. The polypeptide is a subtilisin derived from a strain of Acremonium strictum. The polypeptide is encoded by the nucleotide sequence SEQ ID NO: 1 or sequences at least 90% homologous to the same and has the amino acid sequence SEQ ID NO: 2 or sequences at least 90% homologous to the same.

Abstract: A pharmaceutically acceptable salt, prodrug or derivative compound of the formula I, wherein R1 is selected from H, a (C1-C5) alkyl group and a COR4 group; R2 is selected from H, a (C1-C5) alkyl group and a COR5 group; R3 is selected from H, a (C1-C5) alkyl group, a (C1-C5)-O-alkyl group, a cycloalkyl of (C5-C6) carbon atoms, an aryl group, and an aryl (C1-C5) alkyl group wherein the aryl group can be an unsubstituted aryl or substituted with one or more R6 groups and an NHCOR5 group, or the R2 and R3 groups together with N may form a piperidine, morpholine or piperazine group; R4 is selected from H and a (C1-C5)alkyl group; R5 is selected from an aryl group unsubstituted or substituted with one or more R6, linear or branched(C1-C5) alkyl or pyridyne groups and a pyridine group; R6 is selected from (C1-C5)alkyl groups, halogen and nitro.

Abstract: A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I) wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.